Nicholas Gerard Smedira

Nicholas Gerard Smedira

Auto-generated profile, based on publicly available information

Nicholas Gerard Smedira

Hypertrophic Cardiomyopathy Center, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland Clinic , Cleveland, OH 44195

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2001 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NSNicholas G. Smedira
Nicholas G. Smedira
NMNader Moazami
Nader Moazami
CGCamille M. Golding
Camille M. Golding
PMPatrick M. McCarthy
Patrick M. McCarthy
CACarolyn Apperson-Hansen
Carolyn Apperson-Hansen
DCDelos M. Cosgrove
Delos M. Cosgrove

1 March 2001 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
NSNicholas G Smedira
Nicholas G Smedira
EBEugene H Blackstone
Eugene H Blackstone

1 June 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
KHKevin Hodges
Kevin Hodges
CRCarlos Godoy Rivas
Carlos Godoy Rivas
JAJosé Aguilera
José Aguilera
RBRobert Borden
Robert Borden
AAAlaa Alashi
Alaa Alashi
NSNicholas G. Smedira
Nicholas G. Smedira

14 March 2023 in Circulation
Verified
Journal Article
Closed access
PDF file
MDMilind Y. Desai
Milind Y. Desai
AOAnjali Tiku Owens
Anjali Tiku Owens
JGJeffrey B. Geske
Jeffrey B. Geske
KWKathy Wolski
Kathy Wolski
SSSara Saberi
Sara Saberi
SNSteven E. Nissen
Steven E. Nissen
Background: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM. Methods: A double-blind randomized placebo-controlled multicenter trial at 19 US sites included patients with oHCM on maximal tolerated medical therapy referred for SRT with left ventricular outflow tract gradient ≥50 mm Hg at rest or provocation (enrollment, July 2020–October 2021). The group initially randomized to mavacamten continued the drug for 32 weeks, and the placebo group crossed over to dose-blinded mavacamten from week 16 to week 32. Dose titrations were based on investigator-blinded echocardiographic assessment of left ventricular outflow tract gradient and left ventricular ejection fraction. The principal end point was the proportion of patients proceeding with SRT or remaining guideline eligible at 32 weeks in both treatment groups. Results: From the 112 randomized patients with oHCM, 108 (mean age, 60.3 years; 50% men; 94% in New York Heart Association class III/IV) qualified for week 32 evaluation (56 in the original mavacamten group and 52 in the placebo cross-over group). After 32 weeks, 6 of 56 patients (10.7%) in the original mavacamten group and 7 of 52 patients (13.5%) in the placebo cross-over group met SRT guideline criteria or elected to undergo SRT. After 32 weeks, a sustained reduction in resting left ventricular outflow tract gradient (−33.0 mm Hg [95% CI, −41.1 to −24.9]) and Valsalva left ventricular outflow tract gradient (−43.0 mm Hg [95% CI, −52.1 to −33.9]) was observed in the original mavacamten group. A similar reduction in resting (−33.7 mm Hg [95% CI, −42.2 to −25.2]) and Valsalva (−52.9 mm Hg [95% CI, −63.2 to −42.6]) gradients was quantified in the cross-over group after 16 weeks of mavacamten. After 32 weeks, improvement by ≥1 New York Heart Association class was observed in 48 of 53 patients (90.6%) in the original mavacamten group and 35 of 50 patients (70%) after 16 weeks in the cross-over group. Conclusions: In severely symptomatic patients with oHCM, 32 weeks of mavacamten treatment showed sustained reduction in the proportion proceeding to SRT or remaining guideline eligible, with similar effects observed in patients who crossed over from placebo after 16 weeks. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.

13 May 2025 in Circulation
Verified
Journal Article
Open access
MDMilind Y. Desai
Milind Y. Desai
KWKathy Wolski
Kathy Wolski
AOAnjali Tiku Owens
Anjali Tiku Owens
JGJeffrey B. Geske
Jeffrey B. Geske
SSSara Saberi
Sara Saberi
SNSteven E. Nissen
Steven E. Nissen
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.

1 March 2006 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NSNicholas G. Smedira
Nicholas G. Smedira
CDCornelius M. Dyke
Cornelius M. Dyke
AKAndreas Koster
Andreas Koster
MJMichael Jurmann
Michael Jurmann
DBDevinder S. Bhatia
Devinder S. Bhatia
SASolomon Aronson
Solomon Aronson